ASLAN Pharmaceuticals Pte Ltd (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company, is delighted to invite you to join their upcoming virtual research and development day on Thursday, March 16, 2023! From 10:00 am to 11:30 am ET, you will have a unique opportunity to explore the innovative treatments that ASLAN is developing to transform the lives of patients around the world. Don’t miss out on this exciting event – register now!
Join us for an engaging event featuring Key Opinion Leader Brett King, MD PhD (Yale University School of Medicine). He will discuss the unmet medical need and current limited treatments for patients suffering from alopecia areata (AA), a common autoimmune disease. AA is caused by the activation and proliferation of interferon gamma (IFN-γ)-secreting immune cells which attack the hair follicles, resulting in complete or partial hair loss on the scalp and body. Hear from Brett as he delves into the complexity of this condition and the potential treatment options available.
ASLAN’s stellar leadership team, including Carl Firth PhD (CEO), Stephen Doyle (Chief Business Officer), Alex Kaoukhov MD (Chief Medical Officer) and other members of the senior R&D management team, is excited to announce their recently developed clinical program to investigate farudodstat, a groundbreaking, oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), as a potential treatment for Alopecia Areata (AA). Farudodstat has been shown to effectively inhibit IFN-γ secretion, reduce immune cell proliferation, and protect hair follicles from IP collapse in a human AA disease model. To prove the efficacy of farudodstat in AA, ASLAN plans to launch a proof-of-concept study in the second quarter of 2023.
Dr. Brett King is an esteemed Associate Professor of Dermatology at Yale University, renowned for his pioneering research in the use of Janus kinase (JAK) inhibitors to treat a variety of skin conditions. He has made impressive strides in treating alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, and erosive lichen planus, giving countless patients relief from their skin diseases.
Farudodstat is a revolutionary oral DHODH inhibitor that has been shown to be 30 times more potent than first-generation DHODH inhibitors. Not only does this drug suppress immune cell proliferation and IFN-γ secretion, but it also has a well-tolerated safety profile that makes it an ideal candidate for treating alopecia areata (AA). Studies have indicated that farudodstat can protect against the loss of immune privilege in hair follicles, making it a potential breakthrough treatment option.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company on a mission to transform the lives of patients with innovative treatments. With teams in California and Singapore, the company is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in global Phase 2b and Phase 2 trials for moderate-to-severe atopic dermatitis (AD) patients and dupilumab-experienced AD patients, respectively. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, for alopecia areata and plans to initiate a Phase 2 proof-of-concept trial in the second quarter of 2023. With these cutting-edge treatments, ASLAN is striving to revolutionize healthcare and improve the lives of those suffering from a range of medical conditions.